Anteris Technologies Challenges TAVR Industry to Rethink Disease Management

The transcatheter aortic valve replacement (TAVR) sector has spent two decades refining how valves are delivered, yet clinical outcomes suggest the industry has hit a plateau. Anteris Technologies is attempting to pivot this trajectory by applying a pharmaceutical-style mindset to structural heart disease. Rather than focusing solely on device iteration, the company’s strategy centers on identifying the vast, underserved patient population and proving clinical efficacy through direct, head-to-head comparisons.

At the core of this effort is the PARADIGM trial, which pits the company’s DurAVR THV against current market alternatives. The pressure for such comparative data is mounting as TAVR expands to younger, lower-risk patients. Recent findings from the Evolut Low Risk trial have highlighted concerns regarding long-term durability, showing that repeat intervention rates for TAVR reached 9.8% at seven years, compared to 6% for surgical valve replacement. By prioritizing biomimetic design, Anteris aims to demonstrate that superior blood flow and physiologic restoration are the true metrics of success, moving the conversation beyond mere procedural adoption toward a comprehensive model of disease management.